From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

Inhibition of folate-dependent enzymes by 7-OH-methotrexate

Sholar, P. W., Baram, J., Seither, R. L., & Allegra, C. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90709-5 · Cited by 29

Irinotecan and raltitrexed: an active combination in advanced colorectal cancer

Carnaghi, C., Rimassa, L., Garassino, I. M. G., Zucali, P. A., Masci, G., Fallini, M., Morenghi, E., & Santoro, A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf229 · Cited by 29

Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.

Vandenberg, T. A., Pritchard, K. I., Eisenhauer, E. A., Trudeau, M. E., Norris, B. D., Lopez, P., Verma, S. S., Buckman, R. A., & Muldal, A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1241 · Cited by 29

Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717)

Calvert, A. H., Newell, Jackman, A. L., Gumbrell, L., Sikora, E., Grzelakowska-Sztabert, B., Bishop, J., Judson, I. R., Harland, S. J., & Harrap, K. R. (1987) · PubMed · doi:10.25405/ncl.34562562 · Cited by 29

Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.

Stewart, J. A., McCormack, J. J., Tong, W. P., Low, J. B., Roberts, J. D., Blow, A. J., Whitfield, L. R., Haugh, L. D., Grove, W. R., & Grillo-López, A. J. (1988) · PubMed · Cited by 28

Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.

Rosati, G., Rossi, A., Germano, D., Reggiardo, G., & Manzione, L. (2003) · PubMed · Cited by 28

Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations

Goh, B. C., Ratain, M. J., BERTUCCI, D. C., Smith, R., Mani, S., Vogelzang, N., Schilsky, R. L., Hutchison, M., Smith, M., Averbuch, S. D., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1476 · Cited by 27

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study

Punt, C. J. A., Keizer, H. J., Douma, J., Skovsgaard, T., Schüller, J., Muller, E. W., ten Napel, C. H. H., Croles, J. J., Lochs, H. H., Zhang, J., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf045 · Cited by 27

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial

Comella, P., Vita, F. D., Mancarella, S., Lucia, L. D., Biglietto, M., Casaretti, R., Farris, A., Ianniello, G. P., Lorusso, V., Avallone, A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008375705484 · Cited by 27

A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections

Jolivet, J., Landry, L., Pinard, M.-F., McCormack, J. J., Tong, W., & Eisenhauer, E. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253973 · Cited by 26

Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.

Bruckner, H. W., Jj, L., & Dm, S. (1982) · PubMed · Cited by 26

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

Bissett, D., McLeod, H. L., Sheedy, B., Collier, M. A., Pithavala, Y. K., Paradiso, L. J., Pitsiladis, M., & Cassidy, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1601 · Cited by 25

Metastatic bladder cancer: Advances in treatment

Stadler, W. M., Kuzel, T. M., Raghavan, D., Levine, E. G., Vogelzang, N. J., Roth, B. J., & Dorr, F. A. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00337-1 · Cited by 25

New antifolates in clinical development.

Takimoto, C. H. M., & Allegra, C. J. (1995) · PubMed · Cited by 25

Drug-company decision to end cancer trial

Lancet, T. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00320-7 · Cited by 25

Clinical Resistance to Antimetabolites

Spears, C. P. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30101-1 · Cited by 24

Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887

Mendelsohn, L. G., Worzalla, J. F., & Walling, J. M. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_12 · Cited by 24

Raltitrexed (TomudexTM), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor

Hughes, L. R., Stephens, T. C., Boyle, F. T., & Jackman, A. L. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_6 · Cited by 24

Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed

Schmid, K. E., Kornek, G. V., Schüll, B., Raderer, M., Lenauer, A., Depisch, D., Lang, F., & Scheithauer, W. (2003) · Oncology Research and Treatment · doi:10.1159/000071621 · Cited by 24

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study

Gandara, D. R., Edelman, M. J., Crowley, J. J., Lau, D. H., & Livingston, R. B. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050710 · Cited by 24

A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group trial

Weiss, G. R., Liu, P. Y., O'Sullivan, J., Alberts, D. S., Brown, T. D., Neefe, J. R., & Hutchins, L. F. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90309-7 · Cited by 23

A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study

X., C., Steen, P. D., Rowland, K. M., Niedringhaus, R. D., Fitch, T. R., Kugler, J. W., Hillman, D. W., Perez, E. A., Ingle, J. N., & Adjei, A. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj054 · Cited by 23

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

Feliú, J., Salud, A., Escudero, P., López‐Gómez, L., Pericay, C., Castañón, C., de Tejada, M. R. L., Rodríguez-García, J. M., Martínez, M. P., Martín, M. S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601713 · Cited by 22

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer

Aparicio, J., Vicent, J. M., Maestu, I., Garcera, S., Busquier, I., Bosch, C., Llorca, C., Díaz, R., Fernández-Martos, C., & Galán, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg285 · Cited by 22

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement

Wedge, S. R., Laohavinij, S., Taylor, G. A., Boddy, A. V., Calvert, H., & Newell, D. R. (1995) · PubMed · doi:10.25405/ncl.34088034 · Cited by 22

Trimetrexate: Predictors of Severe or Life-Threatening Toxic Effects

Eisenhauer, E. A., Zee, B. C.-Y., Pater, J. L., & Walsh, W. R. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1318 · Cited by 22

Activity of raltitrexed and gemcitabine in advanced pancreatic cancer

Kralidis, E., Aebi, S. P., Friess, H., Büchler, M. W., & Borner, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg150 · Cited by 22

A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer

Richards, D. A., Kindler, H. L., Oettle, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4007 · Cited by 22

O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer

Scagliotti, G. V., Kortsik, C., Manegold, C., Dark, G. G., Crinò, L., O'Brien, M. E. R., Rosell, R., Kayitalire, L., Paul, S., & Paz-Ares, L. G. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91929-5 · Cited by 21

A phase II trial of pemetrexed in patients with metastatic renal cancer

Thödtmann, R., Sauter, T., Weinknecht, S., Weißbach, L., Blatter, J., Ohnmacht, U., & Hanauske, A.-R. (2003) · Investigational New Drugs · doi:10.1023/a:1025480914273 · Cited by 21

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

Casper, E. S., Schwartz, G. K., Johnson, B. E., & Kelsen, D. P. (1992) · Investigational New Drugs · doi:10.1007/bf00944187 · Cited by 21

Phase II Evaluation of Oral Trimetrexate in Mixed Mesodermal Tumors of the Uterus: A Gynecologic Oncology Group Study

Fowler, J. M., Blessing, J. A., Burger, R. A., & Malfetano, J. H. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6621 · Cited by 21

Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors

de Jonge, M. J. A., Punt, C. J. A., Sparreboom, A., Planting, A. S. T., Peters, M. E. W. J., van de Schraaf, J., Jackman, A. L., Smith, R., Mulder, P. H. M. D., & Verweij, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.057 · Cited by 21

A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer

Smith, D. B., & Gallagher, N. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00271-5 · Cited by 21

A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma

MacKay, H. J., McInnes, A., Paul, J., Raby, N., Lofts, F. J., McDonald, A. C., Soukop, M., Fullarton, G. M., Harris, A. L., Garcia-Vargas, J. E., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012552823543 · Cited by 21

Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.

Farrugia, D., Aherne, G. W., Brunton, L., Clarke, S. J., & Jackman, A. L. (2000) · PubMed · Cited by 21

Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial

Neri, B., Doni, L., Fulignati, C., Perfetto, F., Turrini, M., Andréoli, F., Pantalone, D., Pernice, L. M., Taruffi, F., Martini, V., et al. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200208000-00006 · Cited by 21

Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06

Maughan, T., James, R. D., Kerr, D. J., Ledermann, J. A., McArdle, C. S., Seymour, M., Johnston, C., & Stephens, R. J. (2000) · UCL Discovery (University College London) · Cited by 21

Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?

Evans, W. E., Relling, M. V., Boyett, J. M., & Pui, C. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00128-2 · Cited by 20

Correlates of Severe or Life-Threatening Toxic Effects From Trimetrexate

Grem, J. L., Ellenberg, S. S., King, S. A., & Shoemaker, D. D. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1313 · Cited by 20

The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy

Stewart, A. L., Margison, J. M., Wilkinson, P. M., & Lucas, S. B. (1985) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00434358 · Cited by 20

Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer

Harding, M. J., Cantwell, B. M. J., Milstead, R., Harris, A. L., & Kaye, S. B. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.143 · Cited by 19

Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung Cancer

Kris, M. G., DʼAcquisto, R. W., Gralla, R. J., Burke, M. T., Marks, L. D., Fanucchi, M. P., & Heelan, R. T. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00006 · Cited by 19

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis

Budman, D. R., Johnson, R., Barile, B., Bowsher, R. R., Vinciguerra, V. P., Allen, S. L., Kolitz, J. E., Ernest, S., Kreis, W., Zervos, P. H., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000272 · Cited by 19

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer

de Vries, E., Gietema, J. A., Workman, P., Scott, J. E., Crawshaw, A., Hj, D., Dennis, I. F., Mulder, N., Sleijfer, D., & Willemse, P. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.400 · Cited by 19

Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.

Leiby, J. M. (1988) · PubMed · Cited by 19

A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

Schornagel, J. H., Verweij, J., de Mulder, P. H. M., Cognetti, F., Vermorken, J. B., Cappelaere, P., Armand, J., Wildiers, J., Clavel, M., Kirkpatrick, A., et al. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058156 · Cited by 19

Trimetrexate in advanced carcinoma of the esophagus

Alberts, A. S., Falkson, G., Badat, M., Terblanche, A. P. S., & Schmid, E. U. (1988) · Investigational New Drugs · doi:10.1007/bf00173651 · Cited by 18

Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

Blay, J., Judson, I. R., Rodenhuis, S., Hermans, C., Smith, M. P., Glabbeke, M. M. V., & Verweij, J. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199911000-00002 · Cited by 18

Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug

Takemura, Y., Gibson, W. H., Kimbell, R., Kobayashi, H., Miyachi, H., & Jackman, A. L. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01226268 · Cited by 17

A Phase II Trial of Edatrexate in Patients with Advanced Renal Cell Carcinoma

Dreicer, R., PROPERT, K. J., Kuzel, T. M., Kirkwood, J. M., O'Dwyer, P. J., & Loehrer, P. J. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199706000-00008 · Cited by 17

A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.

Plummer, R., Rees, C., Hughes, A. N., Beale, P. J., Highley, M., Trigo, J. M., Gokul, S., Judson, I. R., Calvert, H., Jackman, A. L., et al. (2003) · PubMed · Cited by 17

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

Moore, D. F., Pazdur, R., Abbruzzese, J. L., Ajani, J. A., Dubovsky, D. W., Wade, J. L., Belt, R. J., Mangold, C., Bready, B., & Winn, R. J. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058810 · Cited by 17

Cisplatin, Raltitrexed, Levofolinic Acid and 5-Fluorouracil in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study

Caponigro, F., Rosati, G., Rosa, P. D., Avallone, A., Rosa, V. D., Lucia, L. D., Comella, P., & Comella, G. (2002) · Oncology · doi:10.1159/000065470 · Cited by 16

Raltitrexed plus Weekly Oxaliplatin as First-Line Chemotherapy in Metastatic Colorectal Cancer: A Multicenter Non-randomized Phase II Study

Santini, D., Massacesi, C., D’Angelillo, R. M., Marcucci, F., Campisi, C., Vincenzi, B., Pilone, A., Bianco, V., Bonsignori, M., & Tonini, G. (2004) · Medical Oncology · doi:10.1385/mo:21:1:59 · Cited by 16

A Phase II Trial of Edatrexate, Vinblastine, Adriamycin, Cisplastin, and Filgrastim (EVAC/G-CSF) in Patients With Non–Small-Cell Carcinoma of the Lungs

Colón‐Otero, G., Niedringhaus, R. D., Hillman, S. H., Geyer, S. M., Sloan, J. A., Krook, J. E., Windschitl, H. E., Marks, R. S., Wiesenfeld, M., Tschetter, L. K., et al. (2001) · American Journal of Clinical Oncology · doi:10.1097/00000421-200112000-00004 · Cited by 16

Initial clinical studies of piritrexim.

László, J., Brenckman, W. D., Morgan, E., Clendeninn, N. J., Williams, T., Currie, & Young, C. (1987) · PubMed · Cited by 16

Role of N-glycosylation in the structure and function of the methotrexate membrane transporter from CCRF-CEM human lymphoblastic leukemia cells

Matherly, L. H., & Angeles, S. M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90423-5 · Cited by 15

Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era

Schilsky, R. L. (1996) · Stem Cells · doi:10.1002/stem.140029 · Cited by 15

Determinants of trimetrexate lethality in human colon cancer cells

Grem, J. L., Voeller, D. B., Geoffroy, F., Horak, E., Johnston, P. G., & Allegra, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.451 · Cited by 15

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

Roberts, J. D., Shibata, S., SPICER, D. V., McLeod, H. L., Tombes, M. B., Kyle, B., Carroll, M. I., Sheedy, B., Collier, M. A., Pithavala, Y. K., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051012 · Cited by 15

Open label, multi-centre phase II study of raltitrexed (‘Tomudex’) in patients with inoperable squamous-cell carcinoma of head and neck

Clarke, S. J., Zalcberg, J. R., Olver, I., Mitchell, P. L. R., Rischin, D., Dalley, D. N., Green, M., & Davidson, Y. E. (2000) · Annals of Oncology · doi:10.1023/a:1008369629944 · Cited by 15

Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study.

Martoni, A. A., Mini, E., Pinto, C., Al, G., Nobili, S., Dentico, P., Marino, A., Scicolone, S., Angelelli, B., & Mazzei, T. (2003) · PubMed · Cited by 15

Trimetrexate: experience with solid tumors.

Haller, D. G. (1997) · PubMed · Cited by 15

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G. A., Johnston, A. E., & Clendeninn, N. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690146 · Cited by 14

Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines

Li, X.-K., Kobayashi, H., Holland, J. F., & Ohnuma, T. (1993) · Leukemia Research · doi:10.1016/0145-2126(93)90123-3 · Cited by 14

Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma

Schiesel, J. D., Carabasi, M., Magill, G. B., Casper, E. S., Cheng, E., Marks, L. D., Feyzi, J. M., Clendeninn, N. J., & Smalley, R. V. (1992) · Investigational New Drugs · doi:10.1007/bf00873124 · Cited by 14

Overview of MTA in the treatment of non-small cell lung cancer.

Pe, P., & Green, M. R. (1999) · PubMed · Cited by 14

Oxaliplatin and Raltitrexed in the Treatment of Inoperable Malignant Pleural Mesothelioma: Results of a Pilot Study

Maisano, R., Caristi, N., Toscano, G., Aragona, M., Spadaro, P., Amadio, P., Mare, M., Zavettieri, M., & Torre, F. L. (2001) · Tumori Journal · doi:10.1177/030089160108700607 · Cited by 14

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

Tsavaris, N. B., Kosmas, C., Vadiaka, M., & Koufos, C. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-2 · Cited by 13

Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype

Assaraf, Y. G., & Borgnia, M. J. (1993) · Anti-Cancer Drugs · doi:10.1097/00001813-199306000-00018 · Cited by 13

Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group

Muggia, F. M., Blessing, J. A., Homesley, H. D., & Sorosky, J. I. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050786 · Cited by 13

Overcoming methotrexate resistance by a lipophilic antifolate (BW 301U): from theory to models to practice

László, J., Iland, H. J., & Sedwick, W. D. (1985) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(85)90086-x · Cited by 13

Sequential Trimetrexate, 5-Fluorouracil and Folinic Acid Are Effective and Well Tolerated in Metastatic Colorectal Carcinoma

Szelényi, H., Hohenberger, P., Lochs, H. H., Haboubi, N. Y., Berdel, W. E., Thiel, E., & Kreuser, E. D. (2000) · Oncology · doi:10.1159/000012112 · Cited by 13

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.

Rees, C., Beale, P. J., Trigo, J. M., Mitchell, F., Jackman, A. L., Smith, R. P., Douglass, E. C., & Judson, I. R. (2003) · PubMed · Cited by 13

Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.

Laudani, A., Gebbia, V., Leonardi, V. B., Savio, G., Borsellino, N., Cusimano, M. P., Calabria, C., Stefano, R., & Agostara, B. (2004) · PubMed · Cited by 13

Effect of hydration on plasma-methotrexate levels.

Romolo, J. L., Goldberg, N. H., Hande, K. R., & Rosenberg, S. A. (1977) · PubMed · Cited by 13

Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion

Rafi, R., Taylor, Calvete, Boddy, Balmanno, Bailey, Lind, L., Calvert, Webber, Jackson, et al. (1995) · Clinical Cancer Research · Cited by 13

Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity.

Li, W., & Bertino, J. R. (1992) · PubMed · Cited by 12

ZD9331 as Second- or Third-Line Therapy in Patients With Advanced Colorectal Cancer

Schulz, J. J., Keller, A. M., Canfield, V. A., Parker, G., & Douglass, E. C. (2004) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000071944.01707.53 · Cited by 12

A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma

Bleehen, N. M., Newman, H., Rampling, R. P., Ramsay, J., Roberts, J. T., Bedford, P., & Nethersell, A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.407 · Cited by 12

Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer

Punt, C. J. A., Blanke, C. D., Zhang, J., & Hammershaimb, L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf044 · Cited by 12

ChemInform Abstract: Synthesis and Antitumor Activity of 10‐Propargyl‐10‐deazaaminopterin ( VII).

DeGraw, J. I., Colwell, W. T., Piper, J. R., & Sirotnak, F. M. (1994) · ChemInform · doi:10.1002/chin.199445166 · Cited by 12

Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study

Dawson, N. A., Costanza, M. E., Korzun, A. H., Clamon, G. H., Pollak, M., Vogelzang, N. J., Carey, R. W., & Norton, L. (1991) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950190413 · Cited by 12

Raltitrexed plus Oxaliplatin in the Treatment of Metastatic Colorectal Cancer

Cortinovis, D. L., Bajetta, E., Bartolomeo, M. D., Dognini, G. P., Beretta, E., Ferrario, E., Ricotta, R., & Buzzoni, R. (2004) · Tumori Journal · doi:10.1177/030089160409000205 · Cited by 12

Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer

Satō, A., Kurihara, M., Horikoshi, N., Aiba, K., Kikkawa, N., Shirouzu, K., Mitachi, Y., Sakata, Y., & Wakui, A. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00008 · Cited by 11

Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma

Licht, J. D., Gonin, R., & Antman, K. H. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685515 · Cited by 11

Initial clinical trial and pharmacokinetics of Thymitaq TM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

Creaven, P. J., Pendyala, L., Meropol, N. J., Clendeninn, N. J., Wu, E. Y., Loewen, G., Proefrock, A., Johnston, A. L., & Dixon, M. E. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050724 · Cited by 11

Phase II study of fazarabine in advanced head and neck cancer

Kuebler, J. P., Metch, B., Schuller, D. E., Keppen, M. D., & Hynes, H. E. (1991) · Investigational New Drugs · doi:10.1007/bf00183585 · Cited by 11

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

Rader, J. S., Clarke-Pearson, D., Moore, M., Carson, L. F., Holloway, R., Kao, M. S., Wiznitzer, I., & Douglass, E. C. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00491-8 · Cited by 11

A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM)

Janne, P. A., Obasaju, C. K., Simon, G. R., Taub, R. N., Kelly, K. L., Fidias, P. M., Bloss, L. P., & Kindler, H. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7053 · Cited by 11

Trimetrexate in advanced renal cell carcinoma

Witte, R. S., Elson, P. J., Bryan, G. T., & Trump, D. L. (1992) · Investigational New Drugs · doi:10.1007/bf01275483 · Cited by 11

A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours

Hainsworth, J. D., Vergote, I. B., & Janssens, J. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200305001-00003 · Cited by 10

A Phase II Study of Trimetrexate Therapy for Metastatic Colorectal Carcinoma

Ajani, J. A., Abbruzzese, J. L., Faintuch, J. S., Patt, Y. Z., Boman, B. M., Levin, B., Jackson, D. E., & Krakoff, I. H. (1990) · Cancer Investigation · doi:10.3109/07357909009018929 · Cited by 10

Phase II Trial for the Evaluation of Trimetrexate in Patients with Inoperable Squamous Carcinoma of the Esophagus

Falkson, G., RYAN, L. M., & Haller, D. G. (1992) · American Journal of Clinical Oncology · doi:10.1097/00000421-199210000-00007 · Cited by 10

Oral Piritrexim in Advanced Bladder Cancer

Feun, L. G., Savaraj, N., Benedetto, P. W., Waldman, S., Collier, M. A., & Clendeninn, N. J. (1994) · American Journal of Clinical Oncology · doi:10.1097/00000421-199410000-00019 · Cited by 10

Phase II Study of ZD1694 in Patients With Advanced Gastric Cancer

Meropol, N. J., Pazdur, R., Vincent, M. D., Willson, J. K. V., Kelsen, D. P., & Douglass, H. O. (1996) · American Journal of Clinical Oncology · doi:10.1097/00000421-199612000-00020 · Cited by 10

Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.

Kris, M. G., Gralla, R. J., Mt, B., Berkowitz, L., Marks, L. D., Kelsen, D. P., & Heelan, R. T. (1987) · PubMed · Cited by 10

Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer

Woll, P. J., Basser, R., Chevalier, T. L., Drings, P., Manga, G. P., Adenis, A., Seymour, L. W., Smith, F., & Thatcher, N. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.373 · Cited by 9

A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infection schedule

Allegra, C. J., Jenkins, J., Weiss, R. B., Balis, F. M., Drake, J. C., Brooks, J., Thomas, R. V., & Curt, G. A. (1990) · Investigational New Drugs · doi:10.1007/bf00177251 · Cited by 9

Antifolate Polyglutamylation in Preclinical and Clinical Antifolate Resistance

McGuire, J. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_16 · Cited by 9

Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

Cairncross, J. G., Eisenhauer, E. A., Macdonald, D., Rathbone, M. P., Moore, M. J., Sawka, C. A., MacCormick, R., & Kerr, I. G. (1990) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029966 · Cited by 9

Development of Nonpolyglutamatable DHFR Inhibitors

Rosowsky, A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_4 · Cited by 8

Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study

Samlowski, W. E., Lew, D. L., Kuebler, P. J., Kolodziej, M. A., Medina, J. E., Mangan, K. F., Moore, D. F., Schuller, D. E., & Ensley, J. F. (1998) · Investigational New Drugs · doi:10.1023/a:1006178808095 · Cited by 8

Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (ThymitaqTM, AG337)

Hughes, A., & Calvert, A. H. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_10 · Cited by 8

Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days

Sawyer, M. B., Ratain, M. J., BERTUCCI, D. C., Smith, R. P., Schilsky, R. L., Vogelzang, N. J., Shulman, K. L., Douglass, E. C., & Fleming, G. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.148 · Cited by 8

A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer

Brown, T. D., Fleming, T. R., Goodman, P. J., Macdonald, J. S., Pugh, R. P., & O’Rourke, T. J. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199504000-00004 · Cited by 8

Whole-Body Autoradiographic Disposition and Plasma Pharmacokinetics of 5,10-Dideazatetrahydrofolic Acid in Mice Fed Folic Acid-Deficient or Regular Diets †

Pohland, R. C., Alati, T., Lantz, R. J., & Grindey, G. B. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600831006 · Cited by 8

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

Fossella, F. V., Winn, R. J., Holoye, P. Y., Hallinan, B., Raber, M. N., Hoelzer, K. L., Young, J. A., Readling, J., Bowers, B. J., & Hong, W. K. (1992) · Investigational New Drugs · doi:10.1007/bf00944191 · Cited by 8

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatc cancer: A trial with 10-ethyl-deaza-aminopterin

Schultz, P., Kelly, W. K., Begg, C. B., Liebertz, C., Cohen, L., & Scher, H. I. (1994) · Urology · doi:10.1016/s0090-4295(94)80138-x · Cited by 8

Phase I studies of trimetrexate using single and weekly dose schedules

Huan, S. D., Legha, S. S., Raber, M. N., & Krakoff, I. H. (1991) · Investigational New Drugs · doi:10.1007/bf00175090 · Cited by 8

A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck

Degardin, M., Domenge, C., Cappelaere, P., Luboinski, B., Navarrete, M. S., Scott, J. E., & Lefebvre, J.-L. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90156-2 · Cited by 8

Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy

Green, M. D., Sherman, P., & Zalcberg, J. R. (1992) · Investigational New Drugs · doi:10.1007/bf01275477 · Cited by 8

A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion

Bishop, J., Raghavan, D., Olver, I. N., Reece, P. A., Morris, R. G., & Friedlander, M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257627 · Cited by 8

A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study

X., C., Steen, P. D., Rowland, K. M., Niedringhaus, R. D., Kugler, J. W., Ingle, J. N., Perez, E. A., & Adjei, A. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.639 · Cited by 8

Phase II trial of 10-EDAM in advanced soft tissue sarcoma

Knowling, M. A., Bramwell, V. H. C., Eisenhauer, E. A., Boos, G. J., Bodurtha, A. J., & Quirt, I. C. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058985 · Cited by 8

Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer

Treat, J., McCleod, M., Mintzer, D. M., Christiansen, N., Bonomi, P., Monberg, M., Taylor, L., & Obasaju, C. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7130 · Cited by 8

Trimetrexate in advanced hormone-refractory prostate cancer

Witte, R. S., Yeap, B. Y., & Trump, D. L. (1994) · Investigational New Drugs · doi:10.1007/bf00873968 · Cited by 8

Phase II study of edatrexate in advanced head and neck cancer

Kuebler, J. P., Benedetti, J., Schuller, D. E., Ensley, J. F., Grunberg, S. M., Muirhead, M. J., Richert-Boe, K. E., & Marshall, M. E. (1994) · Investigational New Drugs · doi:10.1007/bf00873052 · Cited by 7

Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma

Feun, L. G., Robinson, W. A., Savaraj, N., González, R., Liebmann, A., Offenhauser, K., & Clendeninn, N. J. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199512000-00006 · Cited by 7

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

Iscoe, N., Eisenhauer, E. A., & Bodurtha, A. J. (1990) · Investigational New Drugs · doi:10.1007/bf00216937 · Cited by 7

Phase II Trial of 10-Edam in Patients with Advanced Colorectal Carcinoma

Kemeny, N. E., Israel, K., & O’Hehir, M. A. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199002000-00012 · Cited by 7

Treatment of metastatic malignant melanoma with trimetrexate: A phase II study

Odujinrin, O. O., Goldberg, D. A., Doroshow, J. H., Leong, L., Margolin, K. A., Grove, W. R., Carr, B. I., & Akman, S. A. (1990) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950180110 · Cited by 7

A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma

Verma, S., Quirt, I. C., Eisenhauer, E. A., Iscoe, N. A., Young, V., Bodurtha, A. J., & Davidson, J. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058467 · Cited by 7

AG2034

Boritzki, T. J., Zhang, C., Bartlett, C. A., & Jackson, R. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_13 · Cited by 7

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

Meyers, F. J., Lew, D. L., Lara, P. N., Williamson, S., Marshall, M. E., Balcerzak, S. P., Rivkin, S. E., Samlowski, W. E., & Crawford, E. D. (1998) · Investigational New Drugs · doi:10.1023/a:1006128024879 · Cited by 6

Failure of Pretreatment With Intravenous Folic Acid to Alter the Cumulative Hematologic Toxicity of Lometrexol

Muggia, F. M., Synold, T. W., Newman, E. M., Jeffers, S., Leichman, L. P., Doroshow, J. H., Johnson, K. B., & Groshen, S. G. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1495 · Cited by 6

Phase II Clinical Trial of 5-Fluorouracil, Trimetrexate, and Leucovorin (NFL) in Patients With Advanced Pancreatic Cancer

García, A. A., Leichman, L., Baranda, J. C., Pandit, L., Lenz, H., & Leichman, C. G. (2003) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:34:2-3:079 · Cited by 6

A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer

Cascinu, S., Silva, R. R., Labianca, R., Barni, S., Mattioli, R., Martignoni, G., Frontini, L., Gasparini, G. M., Catalano, V., Baldelli, A. M., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008373817826 · Cited by 6

Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma

Pazdur, R., Moore, D. F., Bready, B., Giannone, L., Maldonado, A., Lin, Y., Fueger, R., Winn, R. J., & Levin, B. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058939 · Cited by 6

Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer

Socinski, M. A., Weissman, C., Hart, L. L., Choksi, J. K., Holladay, C., Prager, D., & Obasaju, C. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7204 · Cited by 6

Phase II trial of trimetrexate in untreated advanced gastric carcinoma

Hantel, A., Tangen, C. M., Macdonald, J. S., Richman, S. P., Pugh, R. P., & Pollock, T. W. (1994) · Investigational New Drugs · doi:10.1007/bf00874448 · Cited by 6

A Phase II Trial of Edatrexate in Previously Treated Squamous Cell Cervical Cancer

Broun, E. R., Iseminger, K. A., Rose, P. G., Lentz, S. L., Malfetano, J. H., Lincoln, S. T., & Mannel, R. S. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199702000-00017 · Cited by 6

A Phase II Trial of Edatrexate in Previously Treated Ovarian Cancer

Broun, E. R., Iseminger, K. A., & Bookman, M. A. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00015 · Cited by 5

ZD9331 in combination with topotecan: phase I and II experience

Benson, A. I., Poplin, E. A., & Vergote, I. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200305001-00004 · Cited by 5

Double Modulation of 5-Fluorouracil by Trimetrexate and Leucovorin in Patients With Advanced Colorectal Carcinoma

Machiavelli, M. R., Salum, G., rez, J. E. P., Ortiz, E. H., Romero, A. O., Bologna, F., Vallejo, C. T., Lacava, J. A., Dominguez, M. E., & Leone, B. A. (2004) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000054903.27866.31 · Cited by 4

Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer

Petruzelka, L. B. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200305001-00002 · Cited by 4

Cancer patients are frequently in negative vitamin b12 balance and exhibit homocysteinemia

Vu, T., Amin, J., Ramos, M., Vanyo, L., & Tisman, G. (1991) · Clinical research · Cited by 4

ChemInform Abstract: Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the N10 Substituent.

Jones, T. R., Calvert, H., Jackman, A. L., Eakin, M. A., SMITHERS, M. L., Betteridge, R. F., Newell, D. R., HAYTER, A. J., STOCKER, A., Harland, S. J., et al. (1986) · ChemInform · doi:10.1002/chin.198606194 · Cited by 4

Raltitrexed (Tomudex) Administration in Patients Failing Multiple Prior Chemotherapy Regimens in Advanced Colorectal Cancer: a Pilot Study

Tsavaris, N., Kosmas, C., Vadiaka, M., Kontos, A., Fotia, M., Angelopoulou, A., Vrizidis, N., Soulla, M., Sougioultzis, S., & Koufos, C. (2002) · Investigational New Drugs · doi:10.1023/a:1014494503230 · Cited by 3

Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck

Huber, M. H., Dimery, I. W., Benner, S. E., Lippman, S. M., Shirinian, M. H., Esparaz, B. T., Frenning, D. H., Guillory-Perez, C., & Hong, W. K. (1994) · Investigational New Drugs · doi:10.1007/bf00873049 · Cited by 3

Phase II trial of edatrexate in patients with metastatic colorectal cancer

Clamon, G. H., Riggs, C. E., Dreicer, R., & Hohl, R. J. (1995) · Investigational New Drugs · doi:10.1007/bf00873145 · Cited by 3

Phase II trial of trimetrexate in advanced esophageal cancer: A southwest oncology group study

Fleming, T. R., Brown, T. D., Ross, S. W., & Macdonald, J. S. (1995) · Investigational New Drugs · doi:10.1007/bf00873146 · Cited by 3

Pemetrexed: Translational research in breast cancer

Hanauske, A.-R. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34278 · Cited by 3

Tomudex

Beale, P. J., & Clarke, S. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_7 · Cited by 3

Thymineless Death

Houghton, P. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_21 · Cited by 3

1997 NIH Budget Request Would Build New Research Hospital

Smigel, K. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.8.495 · Cited by 2

Pemetrexed: Target gene expression in human solid tumors correlates with chemosensitivity patterns

Oberschmidt, O., Eismann, U., Platzek, K., Ehnert, M., Blatter, J., Lahn, M., Ma, D., Clet, N., Paoletti, P., & Hanauske, A.-R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3128 · Cited by 1

Case Report of Acquired Piritrexim Resistance and Collateral Methotrexate Sensitivity in Recurrent Squamous Cell Carcinoma of the Head and Neck

Cvitkovic, E., Domenge, C., & Gandía, D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.15.1248 · Cited by 1

Pemetrexed: Target gene expression in human solid tumors correlates with chemosensitivity patterns

Oberschmidt, O., Eismann, U. H., Platzek, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3128 · Cited by 1

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma

Chang, A. Y., Kim, K., Boucher, H., Bonomi, P., Stewart, J. A., Karp, D. D., & Blum, R. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980115)82:2

Untitled work

Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7

Targeting Metabolism for Cancer Therapy

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

Choi, Y. H., & Yu, A. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 653

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 444

Molecular basis of antifolate resistance

Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338

Metabolic Codependencies in the Tumor Microenvironment

Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 349

Antifolates: the next generation.

Fleming, G. F., & Schilsky, R. L. (1992) · PubMed · Cited by 33

Antifolates in clinical development.

Takimoto, C. H. M. (1997) · PubMed · Cited by 30

New Antifolates: Pharmacology and Clinical Applications

Takimoto, C. H. M. (1996) · The Oncologist · doi:10.1634/theoncologist.1-1-68 · Cited by 47

New antifolates in clinical development.

Takimoto, C. H. M., & Allegra, C. J. (1995) · PubMed · Cited by 25

Current understanding of methotrexate

Leukemias, A., Longo-Sorbello, G. S. A., & Bertino, J. R. (2013)